Comparative pathology of breast cancer in a randomised trial of screening. by Anderson, T. J. et al.
Br. J. Cancer (1991), 64, 108 113
©
Comparative pathology of breast cancer in a randomised trial of screening
T.J. Anderson', J. Lamb', P. Donnan2, F.E. Alexander3, A. Huggins4, B.B. Muir4,
A.E. Kirkpatrick4, U. Chetty5, W. Hepburn2, A. Smith2, R.J. Prescott2 & P. Forrest5*
'Department ofPathology, University ofEdinburgh EH8 9AG; 2Medical Statistics Unit, University ofEdinburgh EH8 9AG;
3Leukaemia Research Fund Centre, Pathology Department, University ofLeeds LS2 9NG; 4Breast Screening Centre, Edinburgh
EHIIJ 2JL; 'Department ofSurgery, Royal Infirmary, Edinburgh EH3 9YW, UK.
Summary In the Edinburgh Randomised Breast Screening Project (EBSP) to December 1988 there were 500
cancers in the study population invited to screening and 340 cancers identified in the control population. The
size and negative lymph node status characteristics of invasive cancers from the two populations were
significantly different (P<0.05). The cancers detected by screening were predominantly 'early stage', with
16% noninvasive (PTIS) and 42% invasive stage I (pTl node negative), whereas cancers were frequently 'late
stage' (more than pT2) and inoperable in nonattenders (44%) and controls (36%). Grouped according to
customary size ranges of invasive cancers, the proportion of cases lymph node positive differed in those screen
detected compared with controls, but the benefit in favour of screen detection was not constant. In com-
parisons of cancers detected at prevalence and incidence screens, as a test of conformity with screening theory,
no significant differences were apparent according to size and lymph node status, yet the characteristics of
histological type of cancer discriminated significantly (P <0.05). When these same histological characteristics
were used to compare survival, the capacity to separate invasive cancers into two groups having good and
poor survival probabilities was evident, with a significant improvement for the screen detected poor survival
group compared with controls (P<0.05).
Reports from several countries have provided the evidence in
favour of screening well women for breast cancer (Shapiro,
1977; Collette et al., 1984; Verbeek et al., 1984; Tabar et al.,
1985; Palli et al., 1986), yet the mortality results from one
randomised controlled trial, the Edinburgh Breast Screening
Project (EBSP) after 7 years of follow up, gave a reduction of
only 17% in the group invited to screening, which was not
statistically significant (Roberts et al., 1990). Whilst the
benefit of screening is ultimately judged by reduction in
mortality (Cole et al., 1980; Chamberlain, 1982) important
aspects of the exercise must be concerned with the com-
parative pathological characteristics of the cancers in
different subgroups of the randomised population. Size and
lymph node status, combined as stage of disease, have been
the standard means of comparison. We have previously dem-
onstrated the utility of histological features to discriminate
between prevalence and incidence screen detected cases
(Anderson et al., 1986). The importance of this is that the
prevalence screen is biased in favour of detecting slow grow-
ing non-aggressive cancers, whilst incidence screens give a
better indication of screening effect. The present analysis
concerns all cancers in the EBSP that had been detected or
diagnosed up to the end of December 1988. The characteris-
tics of size, lymph node status and histological type are used
to interpret the cancer yield in the context of screening
principle and to evaluate the influences on survival.
Materials and methods
Screening population andprocedure
The composition of the study population, the screening pro-
cedure, and the establishment of the pathology register have
been described previously (Roberts et al., 1984). The initial
cohort consisted of 23,226 women aged 45-64 invited for
screening between 1978 and 1981, and 21,904 controls, with
7,206 and 5,576 women being added as updates respectively
during the period 1982-1985. Women were invited for
annual physical examination and biennial mammography;
those in whom an abnormality was detected underwent
further assessment at a review clinic for possible referral for
surgery. Most surgery was performed at one surgical unit
(Department of Surgery, Longmore Hospital), and all
pathological material was submitted to departments of
pathology at the University Medical School or the Western
General Hospital, Edinburgh. The special methods for the
identification and diagnosis of impalpable lesions detected
with mammography alone have been described (Chetty et al.,
1983; Anderson 1989).
Pathology
The pathological information relating to size, lymph node
status and histological nature of cancers was entered on a
standardised form (Roberts et al., 1984) for entry into the
pathology register database of the EBSP. The sections from
all cancers were examined by two pathologists (T.J.A., J.L.,)
and categorised at the time of diagnosis with emphasis on
qualitative evaluation of the histological pattern (or type).
Such histological appearances have been recognised for some
time (Fisher et al., 1975; Azzopardi, 1979; Hutter, 1980) and
the criteria for their characterisation have been recently re-
inforced (Page & Anderson, 1987). The invasive cancers were
arranged in three groups as previously reported (Anderson et
al., 1986): classical special type (ST) with at least 90% of the
tumour showing a designated pattern; variant special type
(VST) with less than 90% but more than 50% composition
as a designated pattern or as a mixture of more than one
designated pattern; not of special type (NST) lacking the
features of the designated special types and corresponding
with the category not otherwise specified (NOS) (Fisher et
al., 1975).
Statistics
Statistical analyses were performed in order to assess the
ability of the cancer characteristics of size (T-stage) and node
status (UICC, 1985) or of histological type, to individually
discriminate between populations and sub-populations. In the
formal analysis of characteristics related to size, only pTI
and pT2 cancers are assessed because there were insufficient
numbers in the study population in the sizes greater than
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this. In terms of node status, histologically known negativity
and known positivity were used in the analysis, whilst the
assessment of histological type was confined to operable
invasive cancers. These analyses were carried out on the
figures for the initial cohort only, to avoid the bias intro-
duced by variable follow-up of women entering as updates,
and have been adjusted for age at survey entry date in four
groups: 45-49, 50-54, 55-59, 60-64. The initial cohort
cancers represent 87% of the total number of cancers. All
analyses were carried out by the statistical package GLIM
using log linear models. In addition the three cancer charac-
teristics of size, lymph node status and histological type were
combined to assess survival from breast cancer using Cox's
regression model, incorporating all cases diagnosed up to the
end of 1988. Logistic regression was used to evaluate the
same combination of characteristics to discriminate between




The total of cancers identified among the initial cohort and
updates in the control and study population up to December
1988 was 840. The distribution of these cancers according to
standard TNM pathological criteria is presented in Table I.
This demonstrates the study group cases according to detec-
tion at screen attendance, as symptomatic cases in
non-attenders or in the interval period (variable) following
attendance in comparison to those in the control group. This
shows the 'early' disease stage predominance in the screen
detected group where 41.7% were pTl node negative (stage
1); conversely, in those who never attended following the
invitation to screen the proportion was 13.2%.
Note that the diagnosis was clinial only for nine cases in
each of control and study group (none screen detected) and
for seven control cases stage was not known. Note also that
the total number of cancers in the study group was 47%
greater than the control population.
From Table I it is apparent that the proportion of node
negative pTl and pT2 (operable) invasive cancers was sub-
stantially higher in the study population (67.2%) than con-
trol group (53.2%). Looking more specifically at screen
detected cases and all operable invasive cancers, the node
negative proportion was greater at prevalence (75.5%) than
incidence screens (68.7%). The relationship of node positive
proportion to increase in size of invasive cancers up to
50 mm is compared with controls in Figure 1. Major reduc-
tion in node positivity occurred in all screen detected groups
except pTlc (11 to 20mm). The major contribution to this
equivalent node positivity was due to the cases detected at
incidence screens (Table IB). Differentiating between screens
that were clinical alone (visit 2, 4, 6) and those that include
routine mammography (visit 3, 5, 7) showed the excess of
node positivity to derive from the former (9 of 17, 53% and








-5 6-10 11-15 16-20 21-30 31-40 341
Cancer size (mm)
Figure 1 The proportion of control (broken line) and screen
detected (solid line) cases with proven lymphatic metastasis is
given for standard invasive cancer size ranges. The total number
of cases in each group is indicated.
Table I Pathology size and node status of cancer according to population or
presentation category (Initial cohort and updates)
A
Pathology size
pTIS pTI pT2 >pT3
Category Node status non-inv. 1-20mm 20-50 >50 Total
Screen Negative 35 (23)* 120 (33) 41 (2) 3 199
detected Positive 0 37 (6) 18 5 60
Unknown 9 (5) 8 (2) 1 (1) 11 29
Non Negative 2 14 (1) 8 4 28
attender Positive 0 10 14 12 36
Unknown 1 5 (1) 3 36 52
Interval Negative 5 (2) 22 (2) 16 (2) 2 45
+ other Positive 1 9 10 11 31
Unknown 2 3 0 3 10
Control Negative 8 63 (3) 38 (1) 17 126
Positive 0 27 37 30 94
Unknown 3 (1) 14 11 75 119
B
Prevalence Negative 19 (14) 53 (7) 18 (2) 0 90
screen Positive 0 11 (2) 7 4 22
Unknown 5 (2) 5 (1) 0 1 11
Incidence Negative 16 (9) 67 (26) 23 3 109
screen Positive 0 26 (4) 11 1 33
Unknown 4 (3) 3 (1) 1 10 18
Three Phyllodes tumours were not included, one each in screen detected,
interval and other and control populations. A further eight study population
cases had unknown presentation. Included in the Totals for unknown node
status are nine cases with clinical diagnosis only in each of control and study
populations and seven cases where stage was not known. *The figures in brackets
refer to the occult cancers.110 T.J. ANDERSON et al.
A total of 211 cases underwent needle localisation biopsy
for impalpable (occult) lesions in the study population and in
80 of these cancer was detected. The pathology size distribu-
tion of these cancers is shown in Table I in bracketed figures.
The screen detected cancers were predominantly pTIS or pT,
the latter with a frequency of node positivity (15.4%) that
was the lowest in the study.
The distribution of the cancers from the initial cohort and
updates according to the histological classification is pre-
sented in relation to the population or subgroup source in
Table II. This shows clearly the increased detection in the
study group of noninvasive cancers (11.2%) and of invasive
cancers with particular histological features (33.3%), an effect
that is evidently attributable to screen detected cancers. Of
particular note among screen detected cancers is the high
proportion of invasive cancers with tubular and cribriform
features, in either classical (8.7%) or variant (10.4%) forms.
The cancer histological characteristics are condensed into
four categories in Table III to highlight the contrasting distri-
bution of the cases in each category among the different
population groups. In the screen detected cases, the propor-
tion of invasive cancers with special histological features,
either in classical or variant forms, was double that in con-
trols. Of interest is the closely similar distribution of invasive
cancers among non attenders to those in controls; conversely,
those in the interval and other groups showed a high propor-
tion of noninvasive and special type invasive cancers, as in
the screen detected cases.
Cancer characteristics as discriminants; size and lymph node
status
In view of the above findings it is relevant to investigate the
ability of these same characteristics to discriminate between
presentation categories, in particular the cancers of
prevalence and incidence screens. The reasons for restricting
populations in this analysis are given in Methods. Table IV
shows the distribution of invasive cancers according to size
(pTl, pT2) in the control and overall study population of the
initial cohort only, giving also the breakdown into prevalence
and incidence screens. Significant differences in the size distri-
bution are evident between cancers of control and study
populations (P <0.05), and also between those of controls
and cancers detected at both prevalence (P <0.05) and
incidence screens (P <0.01). However, no significant size
difference is noted comparing invasive cancers detected at
prevalence and incidence screens.
Table III Histological categories ofcancers according to population
or presentation category (Initial cohort and updates)
Variant Not
Non- Special special special Not
Cateogry invasive type type type known Total
Screen 44 52 61 131 0 288
detected (15.2%) (19.1%) (21.2%) (45.4%)
Non 3 14 13 66 20 116
attender (2.6%) (12.1%) (11.2%) (56.9%) (17.2%)
Interval + 8 13 10 48 7 86
other (9.3%) (15.1%) (11.6%) (55.8%) (8.1%)
Control 11 31 43 209 45 339
(3.2%) (9.1%) (12.7%) (61.7%) (13.3%)
Three Phyllodes tumours were not included, one each in screen
detected, interval and other and control populations. A further eight
study population cases had unknown presentation.
Table IV Distribution of pTl and pT2 invasive cancers according
to presentation category (Initial cohort only)
Category pTl pT2 Total
Prevalence screen 51 21 72
Incidence screen 87 34 121
Screen detected 138 55 193
Interval + other 25 18 43
Non attender 21 19 40
Study cases 184 92 276
Control cases 85 65 150
Table II Histological type of cancer according to population or
presentation category (Initial cohort and updates)
Histological type Screen detected Study group Control group
Non invasive cancer: 44 (15.2) 55 (11.2) 11 (3.2)
Ductal 33 44 9
Lobular 5 5 1
Combined 4 4 1
Unknown 2 2
Invasive cancer
Special type: 52 (18.1) 79 (16.2) 31 (9.1)
Tubular/cribriform 25 30 8
Mucoid 1 4 3
Medullary - 1 3
Papillary 1 1
Lobular 16 24 11
Microinvasive 4 4 3
Other 5 15 3
Variants of special
types: 61 (21.2) 84 (17.1) 43 (12.7)
Tubular/cribriform 30 38 22
Lobular 12 18 9
Medullary - 3
Others 18 25 12
Unknown I
Not of special type: 131 (45.5) 245 (50.0) 209 (61.7)
Unknown - 27 (5.5) 45 (13.3)
Total 288 (100) 490 (100) 339 (100)
Three Phyllodes tumours were not included, one each in screen detected,
interval and other and control populations. A further eight study
population cases had unknown presentation.RANDOMISED BREAST SCREENING PROJECT 111
The same population groupings are maintained to compare
node status in Table V. This shows separately the case
numbers with node status known histologically to be either
negative or positive as well as the total cases in the group.
The salient features to note are that whilst significant
differences occurred for node negativity between control and
study populations (as well as subgroups), for node positivity
only the prevalence screen differed significantly (P <0.05)
from controls. For both known node positivity and
negativity no significant difference was found between
cancers of prevalence and incidence screens. It appears
therefore that whilst size and lymph node status are capable
of distinguishing differences between study group and con-
trols they give no useful measure of discrimination between
cancers of prevalence and incidence screens.
Table VI Histological category of operable invasive cancers
according to presentation category (Initial cohort only)
Variant Not
Special special special
Cateogry type type type
Prevalence screen 14 30 29
Incidence screen 21 26 72
Screen detected 35 56 101
Interval + other 8 5 34
Non attender 7 7 37
Study cases 50 68 172
Control cases 19 28 140
Note that the total number of cases differs from Tables IV and V
as it refers to all operable invasive cancers.
Cancer characteristics as discriminants: histological
characteristics
The final comparisons (Table VI), again relating to the initial
cohorts in both study and control populations, examine the
distribution of the cancers in the three histological categories
ST, VST and NST. In these assessments the significance tests
allow for age at survey entry and apply only to the operable
invasive cancers.
Comparison of study and control groups showed a signifi-
cant difference (P <0.05) in that more invasive cancers with
special characteristics were present among the former. This
difference was highly significant for the screen detected
cancers (P <0.0001). Examining further those cancers
detected by screening, the prevalence cases differed highly
significantly from controls (P <0.001), while the incidence
cases did not. Of particular note is the significant difference
in histological type proportions between the prevalence and
incidence screen cases (P <0.05). In a logistic regression, the
significance of histological type remained after allowance for
size and node status, which themselves were not significant.
Comparisons ofsurvival
The ability of histological characteristics to distinguish sub-
groups of the study population suggest that these characteris-
tics should be examined for influences on survival experience
within the EBSP. Figure 2 shows the survival curves for
control and screen detected cancers according to histological
type in three categories. This shows clearly the survival
advantage of cancers with special histological characteristics
in both groups with almost 90% survivors at 7 years. How-
ever control group cancers lacking such features showed the
poorest survival (60% at 7 years) and there was an identical
experience for this category in non attenders to screening
(data not shown). Among screen detected cases survival was
also poorest for invasive cancers lacking special features
(73% at 7 years), but survival in this group was significantly
better than controls (logrank test, P <0.05).
Using Cox's regression model the length of survival from
diagnosis was significantly greater for the study cases relative
to the controls (Hazard ratio = 0.54; 95% confidence inter-
val = 0.39, 0.74), adjusting for age. This is not surprising, due
Table V Node status of pTI and pT2 invasive cancers according to
presentation category (Initial cohort only)
Known Known
Category negative positive Total
Prevalence screen 56 14 72
Incidence screen 85 31 121
Screen detected 141 45 193
Interval + other 25 15 43
Non attender 15 19 40
Study cases 181 79 276
Control cases 74 53 150
Totals include cases of unknown node status.
to the lea; time bias inherent in an analysis based on survival
from date of diagnosis. However, when pathology size, node
status and histological type are added the relative risk for the
study population becomes non significant (HR = 0.98; 0.71,
1.36). The combination of tumour size (HR = 0.26; 0.16,
0.43) node negative status relative to positive (HR = 0.27;
0.16, 0.46) and histological type (HR = 0.46; 0.29, 0.73) ex-
plain the difference in survival between study and control
cases. This suggests that a combination of these characteris-
tics could provide an early measure of screening performance
before the long term outcome in terms ofmortality is known.
Discussion
Seven year mortality results have already been reported from
this Trial (Roberts et al., 1990) in which it was recognised
that some bias was introduced into the study as a conse-
quence of the 'cluster' effect of the randomisation process.
Nevertheless through comparisons between the subgroups of
the EBSP, this report gives particular attention to the utility
of histological characteristics in the judgement of screening
effect in advance of mortality influence.
Considering first the discriminant measure between
prevalence and incidence screens, neither diminished cancer
size nor node status was useful but histological features were.
These findings have important implications for screening
effect. The theory of screening predicts that prevalence
screens are biased towards slow growing, less aggressive
cancers (Cole & Morrison, 1980; Chamberlain, 1982). The
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Figure 2 The survival curves from date of diagnosis of breast
cancer for control (broken line) and screen detected (solid line)
cases, according to histological type (abbreviations as in text).112 T.J. ANDERSON et al.
high proportion of well differentiated special type invasive
cancers and infrequent node positivity of the prevalence
screen. Such features are less evident at incidence screens,
however, and it is of some concern that a high node positive
frequency was experienced in Edinburgh at the 'clinical only'
incidence visits. One explanation would be that those cases
were missed at the previous 'mammography and clinical'
visits, which were themselves associated with low node
positive frequency; another would be that the lesions were
fast growing, aggressive cancers. To answer this would
require blind retrospective radiological review. Yet concen-
tration of this node positive effect among invasive cancers of
11 to 20 mm size range is of particular interest as it suggests
a threshold effect for detection of some cancers that would
need to be lowered to improve survival probabilities. Such
observations have considerable importance in the context of
the current 3-year interval between screens for the UK pro-
gramme. The conclusions from the Nijmegen project
favoured a 2-year interval (Peeters et al., 1989) and a study
of this aspect in the UK is one of the major new research
initiatives (Chamberlain, 1990).
Nevertheless, histological node status offers some potential
as an early index of screening benefit. In the Swedish Two
Counties study, with a significant mortality benefit to the
population offered screening, there was an unusually low
lymph node positivity for invasive cancers less than 10mm
(Tabar et al., 1987). This experience is remarkable for its
divergence from other reported findings for the 1-10mm
invasive cancer size range, where node positivity seldom
reduces below 20% (Frisell et al., 1987; Carter et al., 1989;
Rosen et al., 1989). Such a reduction was seen here only for
the prevalence (and occult) screen cases but without
significant overall mortality benefit (Roberts et al., 1990).
What may be relevant is to achieve a satisfactory yield of
invasive cancers at incidence screens as well as to obtain
reduction in the node positive proportion below that of the
control population, particularly at 20 mm or less. For exam-
ple, in the Ostergotland component of the Two Counties trial
the node positive proportion for all invasive cancers of
incidence screens was 18% (controls 40%) with 85% of cases
measuring 20 mm or less (controls 59%) (Hatschek et al.,
1989). The comparable figures for EBSP incidence screen
invasive cancers were 28.5% and 47.9% respectively.
Histological discrimination between cancers at prevalence
and incidence screens, noted here and previously (Anderson
et al., 1986) shows similarities with findings reported from
the Ostergotland project where histological grade of
prevalence but not incidence screen cancers differed
significantly from controls (Grontoft, 1988). Preference for
histological type characteristics has been emphasised here in
view of previous associations with significant improved sur-
vival in symptomatic cases (Hutter, 1980; Dawson et al.,
1982; Dixon et al., 1985), and for pragmatic reasons of
biology and natural history. Such classifications have in the
current prospective evaluation been translated successfully to
survival differences in the EBSP at 7 years. These demon-
strate the ready division on standard histological grounds
into cancers with good (special type and variants) and poor
(not special type) survival probabilities. The benefits of
screen detection are apparent, particularly for invasive
cancers with poor survival probabilities, but this could be
attributed to an effect of lead time. Furthermore the possi-
bility that variation in proportions of cancers in these histo-
logical categories at prevalence and incidence screens may
reflect the natural history ofcancer progression with time is a
concept being explored. Certainly the adverse effect of non
attendance, whether in terms of node positivity or histo-
logical characteristics, is readily perceived as a valid explana-
tion for a dilutional effect in reducing the overall benefit to a
population offered screening (Roberts et al., 1990), stressing
the importance of achieving high compliance. This analysis of
pathological data from the EBSP suggests that early judge-
ment of the screening effect ahead of mortality is possible. A
combination of cancer size, node status and histological type
is likely to give a more useful measure than size alone (Day
et al., 1989) in the early assessment of performance in breast
cancer screening, with incidence screens being most infor-
mative.
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